In stock
CJC-1295 no DAC
5MG
$49.99
Frequently bought together
CJC-1295 no DAC (Modified GRF 1-29) is a synthetic analogue of GRF(1-29), the first 29 amino acids of growth hormone-releasing hormone. Four substitutions (D-Ala2, Gln8, Ala15, Leu27) increase its resistance to enzymatic degradation relative to native GHRH(1-29). It carries no Drug Affinity Complex, giving a shorter, more pulsatile reported profile. Studied in non-human models of GHRH receptor binding and somatotropic axis signalling.
Products sold by KÖLD are for Research Use Only. Not intended for human or animal consumption, diagnosis, treatment, or prevention of disease.
Guaranteed safe checkout
Product Disclaimer
Compounds designed for strength, endurance, and recovery pathway research.
Product Features
CJC-1295 no DAC, also called Modified GRF 1-29, is a synthetic analogue of GRF(1-29), the functional fragment of growth hormone-releasing hormone that sermorelin also represents. It incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that reduce susceptibility to the enzymatic degradation seen in native GHRH(1-29). Unlike CJC-1295 with DAC, it lacks the maleimide-based Drug Affinity Complex that covalently binds serum albumin, so its reported half-life is markedly shorter (on the order of 30 minutes) with a more pulsatile signalling profile. Studied by researchers examining GHRH receptor pathways in laboratory models.
How does CJC-1295 no DAC differ structurally from CJC-1295 with DAC? Both share the same four substitutions on the GRF(1-29) backbone. The DAC form adds a Lys30 residue bearing a maleimidopropionyl group that binds albumin. The no-DAC form omits that addition entirely, which is the only structural difference between the two molecules.
What does “Modified GRF 1-29” refer to? The four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) applied to GRF(1-29), the first 29 residues of GHRH. These increase resistance to enzymatic breakdown relative to the native fragment, which is the same sequence sermorelin represents in unmodified form.
Why is the reported half-life shorter than the DAC version? The Drug Affinity Complex in the DAC variant is a maleimide moiety that forms a covalent bond with serum albumin, creating a long-circulating reservoir. Without it, this compound is not albumin-bound, so its reported half-life is far shorter and its profile more pulsatile in studied models.
Before Reconstitution
Store sealed vial in a freezer at -20°C (–4°F)
Keep away from light and humidity
After Reconstitution
Store at 4°C (39°F)
Use within 14 days
Avoid repeated freeze-thaw cycles
This compound is supplied as a lyophilized powder.
Use KÖLD Solution (sterile, lab-grade solvent) if your protocol requires reconstitution.
Reconstitute only when ready to begin your study.
For research use only. Not for human or animal use.
Not intended to diagnose, treat, cure, or prevent any disease.
“The level of trust and transparency behind this research material is unmatched. It gives me confidence in every study I run.”
Frequently Bought Together
KÖLD peptides
CJC-1295 no DAC
$49.99